An Open Label Phase 1b Study of Secukinumab in Patients With Moderate to Severe Papulopustular Rosacea
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Change From Baseline in Papule/Pustule Count at Week 16
研究概览
简要总结
This is a study to determine whether secukinumab is a potential therapy for those with papulopustular rosacea. We will observe whether this drug decreases the size and/or amount and severity of the pustules of those who suffer from rosacea.
详细描述
Rosacea is a common inflammatory skin disease affecting up to 10% of adults. Despite this, the etiology of rosacea is unclear, although there may be a genetic predisposition (Chang et al., 2015). Currently, there is no cure. Rosacea can lead to scarring, itching, burning, and is associated with anxiety and depression (Moustafa et al., 2015), significantly affecting quality of life.
Secukinumab is an antibody that binds to a protein (interleukin (IL)-17A) that is involved in inflammation. When IL-17A is bound to secukinumab, it cannot bind to its receptor, thereby inhibiting its ability to feed the inflammatory response. In clinical trials, secukinumab has been effective for moderate to severe psoriasis (Blauvelt et al., 2015). Recently, human data from all types of rosacea have shown Th1/Th17 polarization profile of the T-cell response, suggesting that anti-IL-17 therapy may be beneficial for rosacea (Buhl et al., 2015). Hence, secukinumab could be effective against rosacea. This proposal is a proof-of-concept study to use secukinumab in open label design for moderate to severe papulopustular rosacea.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •moderate to severe papulopustular rosacea defined clinically using the grading system of Wilkin et al. (2004) as having at least ten lesions (either papules or pustules) on face at time of enrollment
- •age 18 years or greater willing and able to understand and sign informed consent form
排除标准
- •known hypersensitivity to secukinumab
- •topical or oral anti-rosacea medication usage for 28 days prior to enrollment
- •active Crohn's disease, as secukinumab may exacerbate this disease
- •active infection including tuberculosis, hepatitis B or C, human immunodeficiency virus
- •participants with latent tuberculosis will need to have treatment initiated prior to starting study drug
- •pregnant or lactating
- •active and/or uncontrolled medical conditions that may interfere with study procedures or obscure rosacea assessment such as cutaneous lupus
- •use of retinoids within past 3 months of enrollment
- •use of antibiotics within 4 weeks of enrollment
- •use of light based or laser treatment to face within 8 weeks of enrollment
- •use of topical or systemic steroids within 4 weeks of enrollment
- •acne conglobate, acne fulminans, chloracne, severe acne requiring systemic treatment
研究组 & 干预措施
Secukinumab arm
Participants receive secukinumab (7 doses over a 16-week study period).
干预措施: Secukinumab (Drug)
结局指标
主要结局
Change From Baseline in Papule/Pustule Count at Week 16
时间窗: Baseline, week 16
The total number of papules and pustules on the patient was assessed.
次要结局
- Change From Baseline in Rosacea Quality of Life (RosaQoL) Score at Week 16(Baseline, week 16)
- Count of Participants With ≥ Grade 3 Adverse Events(16 weeks)
- Change From Baseline in Clinician's Global Severity Score for Rosacea at Week 16(Baseline, week 16)
- Change From Baseline in Immune Infiltrates in Papulopustular Rosacea Lesions at Week 16(Baseline, week 16)
- Change From Baseline Papule/Pustule Count at Week 12(Baseline, week 12)
- Change From Baseline in Clinician's Global Erythema Assessment Score at Week 16(Baseline, week 16)
研究者
Anne Chang
Associate Professor
Stanford University